Click here to take the survey on HE Benefit-risk
The management of multiple sclerosis has begun to shift away from the traditional escalation model – intensifying therapy in response to ongoing disease activity or progression – to one in which high-efficacy DMTs are used earlier in the clinical course. Read More
A new review has summarized three potential biomarkers of adverse effects that may occur with disease-modifying therapies used in the treatment of MS (Kreft et al. J Neurol 2022;269:5192-5193). (Free references below.) All results are preliminary and further validation is required.
Long-acting disease-modifying therapies do not appear to increase the risk of complications following autologous hematopoietic stem cell transplantation (aHSCT), according to a retrospective study from Sweden (Kvistad et al. J Neurol Neurosurg Psychiatry 2022;93:844-848). Read More
Use of disease-modifying therapies for MS changed substantially during the pandemic among clinicians and patients, according to two studies presented at the European Academy of Neurology (EAN) 2022 annual meeting. Read More